Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II lenalidomide + rituximab in relapsed indolent non-follicular non-Hodgkin lymphoma
2008-001591-80Phase 2Completed
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and rituximab in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL) and 5 more, sponsored by Gruppo Italiano Studio Linfomi. Primary endpoints: Overall response rate, Tumor control rate and 1 more. Started Jan 2009; status: completed.
02
Drugs
lenalidomiderituximab
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2008-001591-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001591-80.